⁸⁹Zirconium-labelled girentuximab (⁸⁹Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma.

ABSTRACT:

Introduction

Bladder cancer is a lethal disease with a rising incidence on a background of limited conventional imaging modalities for staging (either CT of the chest-abdomen-pelvis or 18F-fluorodeoxyglucose positron emitting tomography (FDG-PET/CT)). CT is known to have relatively low sensitivity for detecting low volume metastatic disease, an important goal when considering surgical interventions entailing significant potential morbidity. FDG is also limited, being predominantly renally excreted and, therefore, producing intense non-specific activity in the urinary tract, which limits its utility to detect bladder and upper tract lesions, or nodal metastases in close proximity to the urinary tract. ⁸⁹Zirconium-labelled girentuximab (⁸⁹Zr-TLX250) may have uti

SUBMITTER: Al-Zubaidi M 

PROVIDER: S-EPMC9014075 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature